Isoxazole Derivatives Modulating 5-HT2A Receptor Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that can effectively treat disorders related to the 5-HT2A serotonin receptor, particularly those affecting the cardiovascular system, with requirements for physical and chemical stability and favorable pharmacokinetic properties.
Innovation Solution
A compound of Formula (I) and its pharmaceutically acceptable salts, which can modulate the activity of the 5-HT2A serotonin receptor, are used in pharmaceutical compositions to treat disorders such as coronary artery disease, myocardial infarction, and blood clot formation, offering therapeutic benefits through modulation of the receptor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing 5-HT2A modulators are used to treat cardiovascular disorders, then therapeutic effect is achieved, but physical and chemical stability and pharmacokinetic properties are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of 5-HT2A modulators through varying substituents at different positions (R1-R6 groups) to optimize both therapeutic efficacy and physical-chemical stability. The structure-activity relationship studies identify specific parameter ranges that simultaneously improve cardiovascular therapeutic effects and molecular stability.
Solution Approach 2:
The invention creates composite molecular structures combining the core 5-HT2A modulator scaffold with various functional groups and substituents. These composite structures integrate multiple pharmacophores that work synergistically to enhance both therapeutic activity and pharmacokinetic properties including stability, solubility, and metabolic resistance.
2Reliability
If existing 5-HT2A modulators are used to treat cardiovascular disorders, then therapeutic effect is achieved, but pharmacokinetic properties are unfavorable
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by adjusting molecular weight, lipophilicity, and hydrogen bonding capacity through selective substitution patterns. These parameter changes directly influence absorption, distribution, metabolism, and excretion (ADME) properties to achieve favorable pharmacokinetic profiles while maintaining therapeutic efficacy.
Solution Approach 2:
The invention employs preliminary structural optimization to pre-establish compounds with improved pharmacokinetic properties before clinical evaluation. This includes designing molecules with enhanced metabolic stability and reduced clearance rates from the outset, rather than attempting to improve these properties after initial compound identification.
Data Source
AI summary
Provided is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, that is a modulator of 5-HT2A and can be used in treating diseases and disorders associated with 5-HT2A serotonin receptor expression and/or activity. Thus, also provided are methods of treating 5HT2A-related diseases and disorders.